Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Authored Items
Truseltiq (Infigratinib) New Targeted Therapy FDA Approved for Advanced or Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations
Loretta Fala, Medical Writer
JHOP - August 2021 Vol 11, No 4 in Drug Profiles/Updates, Cholangiocarcinoma
Daurismo (Glasdegib) Approved, in Combination with Low-Dose Cytarabine, for Newly Diagnosed Acute Myeloid Leukemia in Older Adults or Those Unfit for Intensive Chemotherapy
Loretta Fala, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals in FDA Updates, Leukemia
Erleada (Apalutamide) First Drug Approved by the FDA for Nonmetastatic Castration-Resistant Prostate Cancer
Loretta Fala, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals in FDA Updates, Prostate Cancer, Drug Profiles/Updates
Libtayo (Cemiplimab-rwlc), a PD-1 Inhibitor, First Drug Approved by the FDA for Patients with Advanced Cutaneous Squamous-Cell Carcinoma
Loretta Fala, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals in FDA Updates, Skin Cancer
Lorbrena (Lorlatinib) Approved for the Treatment of Metastatic Non–Small-Cell Lung Cancer with ALK Mutation
Loretta Fala, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals in FDA Updates, Lung Cancer
Vizimpro (Dacomitinib) Approved for First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer with EGFR Mutation
Loretta Fala, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals in FDA Updates, Lung Cancer
Yonsa (Fine-Particle Abiraterone Acetate) New Formulation Approved for Metastatic Prostate Cancer
Loretta Fala, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals in FDA Updates, Prostate Cancer
Kymriah (Tisagenlecleucel) for Young Patients with Acute Lymphoblastic Leukemia: First FDA-Approved Gene Therapy
Loretta Fala, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals in FDA Updates, Leukemia
Verzenio (Abemaciclib) a New CDK4/CDK6 Inhibitor Approved for HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Loretta Fala, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals in FDA Updates, Breast Cancer
Yescarta (Axicabtagene Ciloleucel) Second CAR T-Cell Therapy Approved for Patients with Certain Types of Large B-Cell Lymphoma
Loretta Fala, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals in FDA Updates, Lymphoma
Lartruvo (Olaratumab) a Novel First-Line Treatment Approved for Patients with Advanced Soft-Tissue Sarcoma
Loretta Fala, Medical Writer
2017 Second Annual Oncology Guide to New FDA Approvals in Drug Profiles/Updates, FDA Updates
Portrazza (Necitumumab), an IgG1 Monoclonal Antibody, FDA Approved for Advanced Squamous Non–Small-Cell Lung Cancer
Loretta Fala, Medical Writer
2016 First Annual Oncology Guide to New FDA Approvals in Drug Profiles/Updates, FDA Updates
Last modified: May 12, 2016
© Amplity Health. All rights reserved.